March 3, 2009 in Features

More doctors advising wait-and-see for some prostate cancers

Stephanie Desmon Baltimore Sun
Baltimore Sun photo

Dr. H. Ballantine Carter, a Johns Hopkins urologist and oncologist, recommended a wait-and-see approach for Peter Bentey, who suffers from early stages of prostate cancer. Baltimore Sun
(Full-size photo)

Simpler test on horizon

Scientists have made a discovery that could lead to a simple test to help determine which men who have prostate cancer require treatment and which do not.

Researchers at the University of Michigan analyzed 1,126 molecules produced by the body in 262 samples of tissue, blood or urine from men who were healthy or had early-stage prostate cancer, or prostate cancer that had spread.

They found that one substance, sarcosine, was particularly elevated in men with advanced prostate cancer. In fact, it appeared to be a better indicator of advancing prostate cancer than testing for prostate-specific antigen (PSA), which is what doctors primarily rely on now.

Because sarcosine can be detected in urine, it could potentially be used for a simple urine test to identify men requiring treatment.

In addition, tests indicate that sarcosine may play a direct role in making prostate cancer more aggressive. When the researchers added the substance to benign prostate cells in the laboratory, the cells became invasive. So drugs that block its activity could potentially be used to improve treatment.

The researchers cautioned, however, that much more study is needed to confirm the findings and determine how well it would work as a screening test.

– Rob Stein, Washington Post

BALTIMORE – When Peter Bentey was diagnosed with prostate cancer, the doctor told him that he needed surgery. So did the doctor who gave him a second opinion. And the third. And the fourth.

Prepared to have his prostate removed, Bentey kept an appointment with Dr. H. Ballantine Carter, a Johns Hopkins urologist and oncologist. Carter looked at Bentey’s blood work and did his own biopsy.

The doctor’s conclusion? Bentey had prostate cancer, but the New Jersey man did not need surgery. At least not right away.

Bentey’s cancer appeared to be growing slowly, so Carter recommended a wait-and-see approach.

“He said, ‘You’re going to die someday, but I don’t think it’s going to be of prostate cancer,’ ” Bentey recalls.

That was in 2002. A couple of weeks ago, Carter gave him the all-clear for another six months.

Nearly half of the men diagnosed with prostate cancer in the United States have what is considered a low-grade disease, which many doctors say is unlikely to kill and does not require immediate treatment, be it surgery or radiation.

But just a fraction of those men – less than 10 percent, by most estimates – delay. Instead they opt for what Carter and many others say could be unnecessary treatment with side effects that can harm urinary and sexual function.

“The knee-jerk reaction that everyone with prostate cancer needs curative intervention may not be the best approach,” Carter says.

Leading prostate cancer experts agree that close monitoring of the disease – a process known in some circles as watchful waiting, in others as active surveillance – probably is the best course for a large number of men.

But few long-term studies have been done to confirm that, because few men are willing to participate in research in which the cancer is left untreated.

Even longtime proponents of active surveillance say the decision of which avenue to pursue is complicated by the fact that some of the men who wait will end up with advanced cancer – and the small possibility that it cannot be cured.

“It flies in the face of the American approach to disease, which is, “I’ve got to do something now,’ ” Carter says.

Dr. Ian Thompson, chairman of urology at the University of Texas Health Sciences Center, agrees.

“Men look at prostate cancer and they think cancer – ‘the Big C.’ And they think, like pancreatic cancer and lung cancer, ‘I must treat it,’ ” Thompson says.

“But it’s a different disease … than many other cancers.”

In the past two decades, the number of American men diagnosed with prostate cancer has skyrocketed – there were an estimated 186,000 new cases last year – as a blood test that looks for a protein called prostate-specific antigen (PSA) has become more routine.

Early detection has led to a reduction in deaths, from roughly 31,000 annually to about 27,000. But it also has led to many more surgeries. For every 20 to 100 more people treated, doctors say, one life is saved.

Thanks to PSA, many of the cancers being found are much smaller – and less dangerous – than those that had been discovered through physical exams.

So the question has become: What should be done about them?

“That really is the big conundrum in prostate cancer, whom to treat,” says Dr. Howard Parnes, chief of the prostate and urological research group at the National Cancer Institute in Bethesda. “Many more men die with prostate cancer than from prostate cancer.”

In determining whether a patient is a candidate for active surveillance, Carter looks at PSA levels, whether a tumor is palpable during a physical exam and a score based on the microscopic appearance of cancer cells in prostate tissue, which gives an idea of a cancer’s aggressiveness.

Carter, like other doctors, cannot say with certainty that the cancer won’t spread if the patient holds off on treatment. What he has been able to do is spot a growing cancer early enough so that the window of opportunity for cure is not closed.

He cautions that he is “incredibly conservative” about whom he chooses for surveillance. Carter rarely includes men in their 50s because if he and his staff are wrong, the chances of harm are greater. Older men are more likely to have other diseases that are likely to claim them before the cancer does.

“More and more doctors are beginning to recognize we are grossly overdiagnosing prostate cancer in this country,” says Dr. Peter C. Albertsen, a Hopkins-trained urologist and a surgeon at the University of Connecticut Health Center in Farmington.

But he says “it’s still a vast minority of patients who pick (active surveillance). A lot of doctors don’t even discuss it.”

Even with men who are good candidates for waiting, “you’ve got to spend a lot of time talking patients out of treatment,” says Dr. Peter Scardino, who heads the surgery department at the Memorial Sloan-Kettering Cancer Center in New York.

“I look them in the eyes and say, ‘If I had what you have, I wouldn’t let anyone touch me.’ ”

These emotional conversations often include a wife who says that she doesn’t care about the incontinence or impotence that can result from surgery. “I just don’t want him to die of cancer,” she’ll say.

And after all of that, Scardino says, “you can’t be certain that you’re right.”

Scardino is a proponent of the surveillance approach but says he wants to be sure that patients are fully evaluated and with a repeat biopsy before they choose that route. He says doctors must be sure that a larger cancer is not lurking undiscovered.

Researchers are looking for better markers for which cancers will be aggressive and which will not do harm. Carter hopes that his group of patients will add to that knowledge.

And it is crucial that men on active surveillance stick with the program, even after five years without progression.

“You begin to think it is nothing,” Scardino says.

But because of the way this cancer can grow, it can still turn into something many years later, he says: “With active surveillance, five years is just the beginning.”

Bentey was 53 when he was diagnosed with prostate cancer. After consulting with Carter, he decided to buck those other doctors who had pushed for surgery.

Now 60, he drives to Johns Hopkins from his New Jersey home every six months to see the doctor. Every year or so, he gets a follow-up biopsy.

“I feel comfortable with the decision,” he says. “I’ve met four or five people who said I was crazy. … I don’t feel that way. So far, I’ve had seven very good years.”

Thoughts and opinions on this story? Click here to comment >>

Get stories like this in a free daily email